*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Atlanta, GA | Posted: December 16, 2011
Georgia Tech Media Relations
Laura Diamond
laura.diamond@comm.gatech.edu
404-894-6016
Jason Maderer
maderer@gatech.edu
404-660-2926
Summary Sentence:
No summary sentence submitted.Full Summary:
Julie Champion, assistant professor in the School of Chemical & Biomolecular Engineering at Georgia Tech, and Andrew S. Neish, professor of pathology at Emory University School of Medicine, are the recipients of one of two Breakthrough Awards launched by The Kenneth Rainin Foundation (KRF).
Julie ChampionJulie Champion, assistant professor in the School of Chemical & Biomolecular Engineering at Georgia Tech, and Andrew S. Neish, professor of pathology at Emory University School of Medicine, are the recipients of one of two Breakthrough Awards launched by The Kenneth Rainin Foundation (KRF). Their research project on bioengineering bacterially derived immunomodulants for a novel treatment of inflammatory bowel disease received $100,000 in funding.
The Breakthrough Awards Program is designed to provide extended support to existing KRF-funded Innovator Award recipients to further research on Inflammatory Bowel Disease (IBD) and increase the likelihood of a breakthrough discovery. Last year, the team’s proposal received one of the inaugural Innovator awards given by the foundation.
Over the course of the next year, the team’s research will focus on developing effective therapeutics that harnesses the immunomodulatory properties of bacterial molecules for the treatment of IBD. By exploiting the inherent ability of intestinal pathogens to control inflammatory signaling pathways in the human body, the researchers hope to adapt bacterial regulatory molecules and use them as an immunotherapy.
“We
intend to develop a new therapeutic paradigm that utilizes bacterial
immunoregulatory mechanisms and engineers a nanoparticle delivery strategy
essential for clinical viability,” says Champion. Immunomodulators
are agents that alter the immune response by suppression (immunosuppressive) or
enhancement (immunostimulant). “Our research
focuses on exploiting the inherent abilities of intestinal bacteria to
attenuate the symptoms of IBD,” she says.
IBD is a group of inflammatory conditions of the colon and small intestine, including the major types of IBD known as Crohn's disease and ulcerative colitis. Although
the causes of IBD are unknown, medical experts believe the most likely cause is
an immune reaction the body has against its own tissues in the intestine. Approximately
five million people worldwide suffer from some form of IBD, with symptoms that
include pain, bleeding, and debilitation. Current therapeutic options for
patients are largely limited to the use of anti-inflammatory steroids applied
either systemically or locally for the treatment of the symptoms, and removal
of the colon is the only cure at this time.
The Kenneth Rainin Foundation is a private family foundation that funds inspiring and world-changing work. The Innovator Awards Program for IBD Research encourages collaboration in the hope of finding new and better treatments, and ultimately a cure, for ulcerative colitis and Crohn’s disease. The key components for funding consideration include innovation, collaboration, scientific merit, and a high potential for success.
